Welcome to our dedicated page for Bullfrog AI Holdings SEC filings (Ticker: BFRGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BullFrog AI Holdings, Inc. filings document the regulatory record for an AI-enabled drug discovery company with Nasdaq-listed common stock and tradeable warrants. Recent 8-K reports cover business updates, commercial-stage platform activity, Nasdaq stockholders’ equity compliance, at-the-market and equity-line financing facilities, and other material events.
Proxy materials describe annual-meeting procedures, shareholder voting matters, director-nomination deadlines, board governance, and outstanding common-stock information. The filing record also references platform disclosures for bfLEAP® and related AI workflows that support biomedical data analysis, target prioritization, and clinical-development decision processes.
BullFrog AI Holdings, Inc. is registering up to 2,000,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity line. The company will not receive proceeds from Lincoln Park’s resales, but may still sell stock directly to Lincoln Park under a $10 million purchase agreement, with up to $4,099,102 of potential gross proceeds remaining after prior sales of 4,852,318 shares for $5,900,898. As of May 13, 2026, BullFrog AI had 18,541,651 shares outstanding, so issuing all 2,000,000 shares would represent about 9.74% of current shares. The filing highlights prior Nasdaq listing deficiencies, an ongoing minimum bid-price compliance period, and an auditor “going concern” paragraph citing recurring losses, limited cash and the need for additional capital.
BullFrog AI Holdings, Inc. is registering up to 2,000,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity line. The company will not receive proceeds from Lincoln Park’s resales, but may still sell stock directly to Lincoln Park under a $10 million purchase agreement, with up to $4,099,102 of potential gross proceeds remaining after prior sales of 4,852,318 shares for $5,900,898. As of May 13, 2026, BullFrog AI had 18,541,651 shares outstanding, so issuing all 2,000,000 shares would represent about 9.74% of current shares. The filing highlights prior Nasdaq listing deficiencies, an ongoing minimum bid-price compliance period, and an auditor “going concern” paragraph citing recurring losses, limited cash and the need for additional capital.
BullFrog AI Holdings, Inc. reported a Q1 2026 net loss of $1.59 million, improving from a $2.02 million net loss a year earlier as operating expenses declined to $1.61 million. The company generated no revenue in either period, so results reflect primarily research and administrative spending.
Cash and restricted cash totaled $5.19 million at March 31, 2026, up from $2.29 million at year-end, mainly from equity financing. BullFrog raised roughly $4.46 million net through its at-the-market program and equity line, increasing common shares outstanding to 18.45 million and lifting stockholders’ equity to $4.89 million. Management still notes substantial doubt about the company’s ability to continue as a going concern and highlights Nasdaq minimum bid-price compliance risk.
BullFrog AI Holdings, Inc. reported a Q1 2026 net loss of $1.59 million, improving from a $2.02 million net loss a year earlier as operating expenses declined to $1.61 million. The company generated no revenue in either period, so results reflect primarily research and administrative spending.
Cash and restricted cash totaled $5.19 million at March 31, 2026, up from $2.29 million at year-end, mainly from equity financing. BullFrog raised roughly $4.46 million net through its at-the-market program and equity line, increasing common shares outstanding to 18.45 million and lifting stockholders’ equity to $4.89 million. Management still notes substantial doubt about the company’s ability to continue as a going concern and highlights Nasdaq minimum bid-price compliance risk.
BullFrog AI Holdings, Inc. is holding a fully virtual 2026 Annual Meeting of Stockholders on June 11, 2026 at 10:00 a.m. Eastern Time to elect four directors and ratify M&K CPAs, PLLC as independent auditor for 2026.
Stockholders of record at the close of business on April 20, 2026, when 18,530,865 common shares were outstanding, are entitled to vote. Investors can vote online, by telephone, by mail, or during the virtual meeting, and the board unanimously recommends voting FOR all director nominees and FOR the auditor ratification proposal.
BullFrog AI Holdings, Inc. is holding a fully virtual 2026 Annual Meeting of Stockholders on June 11, 2026 at 10:00 a.m. Eastern Time to elect four directors and ratify M&K CPAs, PLLC as independent auditor for 2026.
Stockholders of record at the close of business on April 20, 2026, when 18,530,865 common shares were outstanding, are entitled to vote. Investors can vote online, by telephone, by mail, or during the virtual meeting, and the board unanimously recommends voting FOR all director nominees and FOR the auditor ratification proposal.
BullFrog AI Holdings, Inc. announced that Nasdaq has notified the company it has regained compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), which requires at least $2,500,000 of stockholders’ equity.
The company achieved compliance through sales under its at-the-market sales facility and equity-line-of-credit facility. Management states the strengthened balance sheet provides a capital runway into late 2027. Nasdaq has placed BullFrog AI under a mandatory panel monitor for one year from April 21, 2026, during which any new equity deficiency would not receive additional cure time, though the company could request a new hearing before delisting.
BullFrog AI Holdings, Inc. announced that Nasdaq has notified the company it has regained compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), which requires at least $2,500,000 of stockholders’ equity.
The company achieved compliance through sales under its at-the-market sales facility and equity-line-of-credit facility. Management states the strengthened balance sheet provides a capital runway into late 2027. Nasdaq has placed BullFrog AI under a mandatory panel monitor for one year from April 21, 2026, during which any new equity deficiency would not receive additional cure time, though the company could request a new hearing before delisting.
BullFrog AI Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 11, 2026. This date falls more than 30 days before the anniversary of the 2025 annual meeting, so earlier shareholder proposal and nomination deadlines no longer apply.
Qualified shareholder proposals and director nominations, including those made under SEC Rules 14a-8, 14a-18 and related provisions, must now be received by April 29, 2026. Submissions must satisfy SEC rules, the company’s bylaws and applicable state law, and should be sent to the Company’s Secretary at its Gaithersburg, Maryland address.
BullFrog AI Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 11, 2026. This date falls more than 30 days before the anniversary of the 2025 annual meeting, so earlier shareholder proposal and nomination deadlines no longer apply.
Qualified shareholder proposals and director nominations, including those made under SEC Rules 14a-8, 14a-18 and related provisions, must now be received by April 29, 2026. Submissions must satisfy SEC rules, the company’s bylaws and applicable state law, and should be sent to the Company’s Secretary at its Gaithersburg, Maryland address.
BullFrog AI Holdings, Inc. filed a current report describing a business update and shareholder letter. The company highlighted its first commercial feasibility agreement with a top 5 global pharmaceutical company using its bfLEAP® platform to identify novel drug targets in major depressive disorder.
BullFrog AI stated it has secured financial runway into late 2027 through recent at-the-market and equity-line-of-credit financings, which it believes resulted in stockholders’ equity above $2.5 million, supporting continued execution of its AI-driven drug discovery strategy.
BullFrog AI Holdings, Inc. filed a current report describing a business update and shareholder letter. The company highlighted its first commercial feasibility agreement with a top 5 global pharmaceutical company using its bfLEAP® platform to identify novel drug targets in major depressive disorder.
BullFrog AI stated it has secured financial runway into late 2027 through recent at-the-market and equity-line-of-credit financings, which it believes resulted in stockholders’ equity above $2.5 million, supporting continued execution of its AI-driven drug discovery strategy.
BullFrog AI Holdings, Inc. amends its shelf to permit at-the-market sales of up to $4.3 million of common stock under its existing Sales Agreement with BTIG, LLC. The supplement states the company’s Public Float is approximately $27.0 million based on 18,447,105 shares outstanding as of April 1, 2026, with about 16.0 million held by non-affiliates. The filing notes prior ATM sales of approximately $4.7 million during the prior 12-calendar month period and that one-third of the Public Float equals about $9.0 million, leaving $4.3 million available under General Instruction I.B.6 of Form S-3. Sales will be made "at the market" on mutually agreed terms and the supplement is qualified by the underlying ATM Prospectus.
BullFrog AI Holdings, Inc. amends its shelf to permit at-the-market sales of up to $4.3 million of common stock under its existing Sales Agreement with BTIG, LLC. The supplement states the company’s Public Float is approximately $27.0 million based on 18,447,105 shares outstanding as of April 1, 2026, with about 16.0 million held by non-affiliates. The filing notes prior ATM sales of approximately $4.7 million during the prior 12-calendar month period and that one-third of the Public Float equals about $9.0 million, leaving $4.3 million available under General Instruction I.B.6 of Form S-3. Sales will be made "at the market" on mutually agreed terms and the supplement is qualified by the underlying ATM Prospectus.
BullFrog AI Holdings, Inc. reports that it has raised at least $3.45 million in net proceeds from sales of common stock under its at-the-market sales agreement and equity line of credit facility. The company states that, as a result, it now believes its stockholders’ equity exceeds $2.5 million, the minimum required by Nasdaq Listing Rule 5550(b)(1) for listing on The Nasdaq Capital Market.
The company had previously requested a hearing before an independent Nasdaq Hearings Panel regarding its prior stockholders’ equity deficiency. It cautions that statements about the outcome of any Nasdaq hearing and its ability to regain or maintain listing compliance are forward-looking and subject to risks and uncertainties.
BullFrog AI Holdings, Inc. reports that it has raised at least $3.45 million in net proceeds from sales of common stock under its at-the-market sales agreement and equity line of credit facility. The company states that, as a result, it now believes its stockholders’ equity exceeds $2.5 million, the minimum required by Nasdaq Listing Rule 5550(b)(1) for listing on The Nasdaq Capital Market.
The company had previously requested a hearing before an independent Nasdaq Hearings Panel regarding its prior stockholders’ equity deficiency. It cautions that statements about the outcome of any Nasdaq hearing and its ability to regain or maintain listing compliance are forward-looking and subject to risks and uncertainties.
BullFrog AI Holdings, Inc. entered into a one-year Feasibility Agreement with a top global pharmaceutical company to use its bfLEAP® AI and machine learning platform to identify and prioritize novel drug targets for major depressive disorder (MDD). BullFrog AI can earn milestone payments tied to specific deliverables, and the client receives an option for exclusive rights to a selected final target candidate for three years for its own research and development. The agreement is terminable on notice and includes customary protections around intellectual property, indemnification, and confidentiality. A related press release highlights this as high-profile validation of BullFrog AI’s platform in an MDD market valued at more than $8 billion in 2025 and projected to exceed $11 billion by 2032.
BullFrog AI Holdings, Inc. entered into a one-year Feasibility Agreement with a top global pharmaceutical company to use its bfLEAP® AI and machine learning platform to identify and prioritize novel drug targets for major depressive disorder (MDD). BullFrog AI can earn milestone payments tied to specific deliverables, and the client receives an option for exclusive rights to a selected final target candidate for three years for its own research and development. The agreement is terminable on notice and includes customary protections around intellectual property, indemnification, and confidentiality. A related press release highlights this as high-profile validation of BullFrog AI’s platform in an MDD market valued at more than $8 billion in 2025 and projected to exceed $11 billion by 2032.
BullFrog AI Holdings, Inc. is an early-stage AI-driven biopharmaceutical company using its proprietary bfLEAP™, BullFrog Data Networks™ and bfPREP™ platforms to analyze complex biomedical data and improve drug discovery, rescue failed drugs and support precision medicine development.
The company licenses oncology and liver-disease assets from Johns Hopkins University and George Washington University and maintains multiple royalty-bearing technology licenses with significant future milestone and minimum royalty obligations. It is expanding its data offerings through collaborations, including Lieber Institute for Brain Development and Eleison Pharmaceuticals, and plans to launch a scenario-based decision engine in March 2026.
The filing highlights serious financial and listing risks: as of December 31, 2025, BullFrog held about $2.3 million in cash with an accumulated deficit of roughly $23.3 million, and its auditors expressed substantial doubt about its ability to continue as a going concern. Nasdaq has notified the company of noncompliance with both the stockholders’ equity and minimum bid price requirements, and BullFrog is pursuing an appeal and considering options such as a reverse stock split already approved by stockholders.
BullFrog AI Holdings, Inc. is an early-stage AI-driven biopharmaceutical company using its proprietary bfLEAP™, BullFrog Data Networks™ and bfPREP™ platforms to analyze complex biomedical data and improve drug discovery, rescue failed drugs and support precision medicine development.
The company licenses oncology and liver-disease assets from Johns Hopkins University and George Washington University and maintains multiple royalty-bearing technology licenses with significant future milestone and minimum royalty obligations. It is expanding its data offerings through collaborations, including Lieber Institute for Brain Development and Eleison Pharmaceuticals, and plans to launch a scenario-based decision engine in March 2026.
The filing highlights serious financial and listing risks: as of December 31, 2025, BullFrog held about $2.3 million in cash with an accumulated deficit of roughly $23.3 million, and its auditors expressed substantial doubt about its ability to continue as a going concern. Nasdaq has notified the company of noncompliance with both the stockholders’ equity and minimum bid price requirements, and BullFrog is pursuing an appeal and considering options such as a reverse stock split already approved by stockholders.